---
title: Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
date: '2023-08-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37646702/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20230830181102&v=2.17.9.post6+86293ac
source: N Engl J Med
description: 'CONCLUSIONS: The all-oral combination of mezigdomide plus dexamethasone
  showed promising efficacy in patients with heavily pretreated multiple myeloma,
  with treatment-related adverse events consisting mainly of myelotoxic effects. (Funded
  by Celgene, a Bristol-Myers Squibb Company; CC-92480-MM-001 ClinicalTrials.gov number,
  NCT03374085; EudraCT number, ...'
disable_comments: true
---
CONCLUSIONS: The all-oral combination of mezigdomide plus dexamethasone showed promising efficacy in patients with heavily pretreated multiple myeloma, with treatment-related adverse events consisting mainly of myelotoxic effects. (Funded by Celgene, a Bristol-Myers Squibb Company; CC-92480-MM-001 ClinicalTrials.gov number, NCT03374085; EudraCT number, ...